Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Drug Class List

Drugs in Drug Class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	AB	RX	Yes	Yes	10,857,102		Y
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	10,603,282		Y
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	10,842,751		Y

Market dynamics and patent landscape for HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs

Last updated: April 26, 2026

The HIV-1 NNRTI market is concentrated in three commercially dominant molecules: efavirenz, rilpivirine, and doravirine. Key patent cliffs over the next decade are driven less by NNRTI-only second-generation life cycles and more by platform combinations (single-tablet regimens) and generic penetration. From an IP standpoint, the landscape is defined by (1) early-generation composition and use patents that are largely expired or expiring, and (2) newer entrants (notably doravirine and later rilpivirine formulations) that extend exclusivity through formulation/process and combination protections rather than core NNRTI scaffold patents.

What is the current market structure for HIV-1 NNRTIs?

Concentration by active ingredient

Commercial HIV treatment is dominated by fixed-dose combinations (FDCs) built around a backbone (commonly nucleoside reverse transcriptase inhibitors) plus either an NNRTI or an integrase inhibitor. Within NNRTIs, the active ingredient distribution is skewed toward:

• Efavirenz (legacy anchor for many generic and branded markets)
• Rilpivirine (NNRTI used in several FDCs; label constraints on viral load)
• Doravirine (newer NNRTI with differentiation mainly on tolerability profile)

Efavirenz and rilpivirine have extensive generic competition in most regulated markets, compressing prices and shifting profit pools toward differentiated brands in countries with delayed generic entry, and toward pipeline-specific contracts. Doravirine has had later generic entry timing in key markets, supporting a longer commercial window, but its life cycle is still shaped by patent expiries and by the speed of generic approvals.

Demand drivers that affect IP value

NNRTI demand is influenced by:

• Guideline positioning: NNRTIs increasingly compete with integrase strand transfer inhibitors (INSTIs), limiting room for incremental NNRTI share gains.
• Safety and tolerability: efavirenz has CNS-related tolerability limitations; doravirine has been positioned to address these.
• Dosing and adherence: rilpivirine is dosing-form dependent and has regimen constraints that affect switching patterns.

This matters for patent strategy because brand differentiation has to persist across time to justify litigation and second-cycle spend in a market where INSTI-based regimens dominate first-line adoption.

Which drugs define the HIV-1 NNRTI patent landscape?

The NNRTI class is defined by the molecules below:

NNRTI molecule	Typical commercial role	Patent strategy pattern seen in practice
Efavirenz	Early anchor NNRTI	Core composition/use patents are largely expired or expiring; value driven by formulations, FDC combinations, and market-specific exclusivity windows
Rilpivirine	Second-wave NNRTI	Core patents are largely expired; differentiation comes from specific FDCs, formulations, and dosing regimen claims
Doravirine	Newer NNRTI	Core scaffold patents still drive exclusivity in some jurisdictions; life cycle reinforced by crystalline/solid-state, polymorph, salts, process, and combination protections

How do patent cliffs typically hit the NNRTI segment?

Patent cliff mechanics in NNRTIs

NNRTI exclusivity often ends in stages:

1. Composition of matter for the active ingredient expires (or has already expired in many markets).
2. Specific solid-state forms (polymorphs, salts, hydrates) may provide a second layer.
3. Formulation and process patents can extend exclusivity into the FDC product lifecycle.
4. Combination/regimen claims can add another layer when jurisdictions recognize use-based protections.

Because HIV regimens are sold primarily as FDCs, the practical cliff for revenue is often tied to the first durable generic entry of the most revenue-relevant FDC.

Where generic entry tends to concentrate

• Efavirenz-based FDCs: broad generic penetration; branded share compressed.
• Rilpivirine-based FDCs: generics exist; any remaining premium is localized and contract-driven.
• Doravirine-based FDCs: later generic entry timing relative to older NNRTIs; exclusivity competition remains central.

What does the legal and regulatory framework imply for NNRTI exclusivity?

HIV NNRTI drug approvals and regulatory reference points

For US market access strategy, the Hatch-Waxman framework and Orange Book listings drive generic challenges and launch timing. For global strategy, patent enforcement and regulatory exclusivity interact with each country’s patent linkage and data-exclusivity regime.

Patent landscape work practice in the NNRTI class

A complete strategy focuses on:

• Core patent set (composition, salts/crystals, key intermediates)
• Formulation patents relevant to FDC manufacture and stability
• Combination patents that can block generic manufacturing depending on claim scope
• Method of treatment claims aligned with guideline-real-world regimens

How do specific reference sources map to NNRTI patent positioning?

The backbone IP structure for HIV NNRTIs is widely documented across patent databases and compendia, including:

• FDA’s Orange Book for listed patents tied to approved products and exclusivity windows.
• European patent registers and Espacenet for claim-level mapping across jurisdictions.
• Public patent analytics platforms that compile patent families and legal status.

The most operationally relevant artifact for launch timing is the Orange Book listing for each marketed NNRTI-containing product, because it drives the likelihood and timing of generic litigation and Paragraph IV challenges in the US.

What is the US patent landscape signal using FDA Orange Book listings?

Orange Book listing method for NNRTI FDCs

In the US, the Orange Book records:

• Active ingredient(s)
• Drug product (including dosage form)
• Patent numbers claimed for approval and specific exclusivity triggers

For NNRTIs, patent listings typically include:

• Composition of matter patents on efavirenz/rilpivirine/doravirine and/or their salts/crystals
• Method patents that correspond to dosing or treatment approaches
• Formulation patents tied to specific dosage forms and stability/biopharm aspects

Operational outcome: the last Orange Book patent listed for the highest-volume product is usually the practical “line in the sand” for generic entry.

Where do the patent opportunities concentrate for NNRTI incumbents?

Likely concentration areas by chemical age

• Efavirenz: claims are mostly exhausted; incumbents rely on incremental formulation improvements, and on regulatory exclusivity remnants in certain markets. In the US, Orange Book-linked exclusivity is usually the last meaningful anchor.
• Rilpivirine: similar pattern, with additional leverage in specific FDC presentations and manufacturing-stability improvements where patent coverage remains.
• Doravirine: typically has more live patent families covering solid-state forms and product-specific manufacturing, creating more litigation runway than older NNRTIs.

Likely concentration areas by claim type

For next-cycle exclusivity in NNRTIs, the most litigated claim categories tend to be:

• Solid-state form (crystal form, hydrate)
• Formulation (particle size, excipients for dissolution)
• Process (manufacturing steps that support distinct identity and patentable yield)
• Combination product (regimen-specific claims if recognized)

What are the market implications for investors and R&D planners?

If you are a brand incumbent

• Track the last-living Orange Book patents for the highest-volume FDC, because it determines generic encroachment timing more than the broader class narrative.
• Focus on product-form specific patents rather than scaffold patents, which usually end earlier in older NNRTIs.
• Expect margin compression after generic launches and plan portfolio shifts to INSTI-based or next-generation agents.

If you are a generic entrant

• Target FDC patent lists rather than active-ingredient patents alone; generic entry risk is dominated by combination/formulation claims.
• Use patent-family mapping to identify whether solid-state and formulation patents still remain live in the same jurisdiction for the specific dosage form.

If you are an R&D developer exploring NNRTI differentiation

• Derivative innovation must land on enforceable claim islands: solid-state, formulation, and dosing-constrained use claims that are compatible with label and prescribing patterns.
• Regulatory realism matters: claims that cannot align with approved dosing schedules are harder to enforce.

Key takeaways

• The HIV-1 NNRTI market is concentrated in efavirenz, rilpivirine, and doravirine, with commercial margins increasingly determined by FDC-level generic entry rather than NNRTI-only claims.
• The patent landscape is structured by staged exclusivity: core scaffold first, then solid-state/formulation/process and combination/regimen protections.
• In the US, the practical exclusivity calendar is best read from FDA Orange Book patent listings for each NNRTI-containing product, because it governs generic litigation and launch timing.
• Older NNRTIs (notably efavirenz) show limited remaining patent-driven defensibility in major markets, while doravirine retains more enforceable product-level coverage, supporting a longer brand window.

FAQs

1) Which NNRTI molecules currently dominate the HIV-1 NNRTI category?

Efavirenz, rilpivirine, and doravirine are the core commercially dominant HIV-1 NNRTIs shaping the patent and market dynamics.

2) What typically determines generic launch timing for NNRTI products in the US?

Orange Book-listed patents tied to the specific marketed product and dosage form, particularly those covering FDCs, formulations, and method-of-treatment claims.

3) Are NNRTI scaffold patents usually the main driver of exclusivity late in the lifecycle?

No. For older NNRTIs, scaffold patent families are largely exhausted; remaining exclusivity typically comes from solid-state, formulation, process, and combination protections.

4) Why do FDC patents matter more than NNRTI-only patents?

Most market demand is sold as FDC regimens. Generic manufacturers can face different patent barriers at the dosage-form and combination level even when active-ingredient patents are expired.

5) What is the highest-leverage patent work stream for an NNRTI portfolio owner?

Map and monitor the last-living patents on the highest-volume NNRTI-containing products, using regulatory listing data and jurisdiction-specific legal status.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] European Patent Office. (n.d.). Espacenet: Patent search. https://worldwide.espacenet.com/
[3] U.S. Patent and Trademark Office. (n.d.). Patent Public Search. https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html
[4] NIH. (n.d.). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv